Rigel Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Rigel Pharmaceuticals, Inc. (RIGL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income17.49-25.09-58.57-17.91-29.74-66.89-70.48
Depreciation & Amortization2.231.241.001.160.710.680.59
Stock Based Compensation12.398.8112.399.497.300.000.00
Change in Working Capital0.159.52-29.051.70-30.3213.104.12
Change in Accounts Receivable-11.079.77-24.850.50-5.860.000.00
Change in Inventory0.761.17-2.38-4.88-0.130.000.00
Change in Accounts Payable-3.80-0.373.790.04-0.330.000.00
Change in Other Working Capital14.26-1.050.6814.47-0.370.000.00
Other Operating Activities-0.798.090.6819.546.8113.800.00
Net Cash from Operating Activities31.47-5.74-73.765.88-52.19-41.51-58.83
Investing Activities
Capital Expenditures-0.40-15.00-0.450.63-1.261.46-1.11
Purchases of Investments-35.27-31.21-28.89-79.4148.730.000.00
Sales/Maturities of Investments39.7041.65101.23-79.4148.73-22.2026.07
Other Investing Activities0.100.000.000.000.000.000.00
Net Cash from Investing Activities4.13-4.3072.78-80.0447.47-23.6624.96
Financing Activities
Common Stock Issued1.961.052.1262.682.600.0067.16
Common Stock Repurchased-10.000.000.000.000.000.000.00
Other Financing Activities-3.61-2.63-15.1257.900.000.000.00
Net Cash from Financing Activities-11.6418.376.5562.6812.5711.3771.89
Summary
Net Change in Cash23.968.335.57-11.487.85-53.8038.03
Cash at Beginning of Period32.7924.4618.8930.3722.5276.3238.29
Cash at End of Period56.7532.7924.4618.8930.3776.3276.32
Free Cash Flow31.08-20.74-74.215.25-53.45-42.97-59.93
Supplemental Disclosures
Interest Paid7.045.852.501.501.180.140.00
Income Taxes Paid0.330.000.000.000.000.000.00